Background. In primary hyperparathyroidism, successful parathyroidectomy leads to improved bone mineral density in the majority of cases. Our aim was to further explore the relationship between hypercalciuria, kidney function, and bone recovery after parathyroidectomy. Methods. Bone mineral density, estimated glomerular filtration rate, and 24-hour urinary calcium were analyzed before and one year after parathyroidectomy in a cohort of 150 primary hyperparathyroidism patients (119 women; median age 60 [range 30-80] years) taking part in a clinical trial. The patients were randomized to 1-year daily treatment with either cholecalciferol 1,600 IU and calcium carbonate 1,000 mg or calcium carbonate alone. Results. Baseline 24-hour urinary calcium correlated directly with s-calcium, parathyroid hormone, 25-OH-D, the bone markers beta C-terminal telopeptide of type 1 collagen and procollagen type 1 aminoterminal propeptide, and estimated glomerular filtration rate (r = 0.19-0.30; P < .05) and inversely with age (r = À0.25; P = .004); 24-hour urinary calcium decreased and bone mineral density in lumbar spine and hip increased similarly in the 2 groups. Baseline 24-hour urinary calcium in the highest quartile (>10 mmol/d) was associated with greater increases in all locations. In a multivariable model adjusting for age, sex, smoking, diabetes, body mass index, estimated glomerular filtration rate, baseline bone mineral density, and vitamin D group, the increase in total hip bone mineral density remained independently associated with baseline 24-hour urinary calcium in the highest quartile (>10 mmol/d) and with plasma parathyroid hormone. Patients with persistent increases in 24-hour urinary calcium at follow-up (14%) had similar bone mineral density improvement. Conclusion. Overall, 24-hour urinary calcium > 10 mmol/d was an independent determinant of improvement in bone mineral density and should be taken into account when considering parathyroidectomy. (Surgery 2017;162:429-36.) 
successful PTX and absence of bone recovery. 6 These authors suggested a tubular defect, primary or acquired, as a possible explanation and recommended analysis of urinary calcium after PTX to offer specific treatment to this group of patients. In a recent, randomized, double-blinded study, our group analyzed the effects of vitamin D supplementation on metabolic risk factors and bone recovery after successful PTX. 7, 8 The aim of the present study was to explore the relationship between hypercalciuria, vitamin D status, and bone recovery after PTX.
SUBJECTS AND METHODS
This study is a post hoc analysis based on a randomized trial, ClinicalTrials.gov identifier: NCT00982722, and the study cohort has been described in detail in previous publications. 7, 8 The study complied with the Ethical Principles of the World Medical Association Declaration of Helsinki and was approved by the Ethical Committee and the Medical Products Agency. All patients gave written, informed consent to take part in the study.
A total of 150 (119 women) with pHPT subjected to PTX at the Karolinska University Hospital in Stockholm, Sweden, were enrolled in the study after informed consent. The operative approach was chosen based on the results of preoperative gland localization (ultrasonography, and/or Sestamibi scan). Bilateral exploration was carried out in 44 cases, unilateral with visualization of one normal gland in 50, and focused approach in 56 cases.
Patients were randomized after PTX to 1 year of treatment with either calcium carbonate 500 mg/ 800 IU cholecalciferol twice daily (D+ group) or calcium carbonate 500 mg twice daily (DÀ group). The study was blinded to all the researchers, physicians, nurses, and patients. A 24-hour urine calcium excretion and bone mineral density (BMD) were measured 6 weeks before PTX and postoperatively after 12 months of study medication. Blood samples and 24-hour urinary calcium (PtU-calcium) were collected in the morning from fasting participants. Body mass index (BMI) was calculated at baseline as weight (in kg) divided by the square of height (in meters). Fifteen patients did not complete the study period; the reasons for termination were patient choice (n = 11), emigration (n = 1), death (n = 2), and symptomatic vitamin D deficiency (n = 1). Complete information about PtU-calcium and BMD was available for 129 patients baseline and 124 patients at follow-up 12 months after PTX. BMD. Areal BMD (aBMD, g/cm 2 ) of the total body, total hip, femoral neck, lumbar spine, and nondominant forearm (ultradistal [UD] and onethird proximal radius) was measured with Lunar Prodigy Advance (#PA.41562; GE Healthcare, Diegem, Belgium). The precision error (SD) was 0.009 g/cm2 in the lumbar spine, 0.010 g/cm2 in the total hip, and 0.028 g/cm2 in the radius UD. Osteoporosis was defined as a T-score at any site that exceeded À2.5 SD below the value for white women/men aged 20-29 years.
Statistics. Statistical analysis was performed with the IBM SPSS Statistics (IBM, Armonk, New York), version 23. Because the data did not follow a normal distribution, they are expressed as median and range. Comparisons between groups were performed with the Mann-Whitney U test for unpaired data. Wilcoxon signed rank sum test was used for intraindividual analyses. The KruskalWallis 1-way analysis of variance was used for comparing more than 2 unpaired data, and the v 2 test was used for analyses of the distribution of categorical variables between groups. Relationships between variables were assessed with Spearman r-correlation test and in multivariable linear regression models with adjustment for possible confounders. All tests were 2-tailed.
RESULTS
The clinical characteristics of the cohort are presented in Table I (r = 0.30; P < .001), PTH (r = 0.19; P = .022), 25OHD (r = 0.19; P = .028), and eGFR (r = 0.21; P = .015) and inversely to age (r = À0.25; P = .004). Patients with PtU-calcium in the highest quartile were younger and had greater levels of Ca 2+ , PTH, 25OHD, and P1NP and a greater total hip BMD (Table II) .
A total of 135 patients completed the study period. Patients in the D+ group had greater 25OHD than those in the DÀ group at follow-up (Table II) . The levels of Ca 2+ , eGFR, and PtUcalcium did not differ (P > .05). PtU-calcium decreased similarly in the 2 groups (Table II) . The increases in BMD in the lumbar spine and total hip were similar in the D+ and DÀ groups; BMD in the distal radius improved only in the D+ group (Fig 1) . With the patients divided into PtU-calcium quartiles at baseline, BMD increased most in those in the highest quartile (>10 mmol/d) in all locations except in the one-third proximal radius in both groups (Table III, Fig 1) . When the subgroup of patients with osteoporosis (T-score in any location # À2.5) was analyzed separately, a similar relationship was found between PtU-calcium in the highest quartile (Q IV ; > 10 mmol/d) (Fig 2) . Adjustment of the PtU-calcium for body weight did not change the results except for a minor increase in BMD in the ultradistal radius in the subgroup with osteoporosis (D BMD 0.8 [À0.5 to 2.0]%; P = .035). The 24-hour urinary creatinine was analyzed in 113 patients (range 2.0-20.7; median 9.2 mmol/24 h). Patients with the 24-hour urinary secretion in the highest quartile had the greatest ratio of urinary calcium/creatinine clearance, and correction for urinary creatinine excretion did not infer on the results (data not shown).
Persistent increases in PtU-calcium greater than the reference range (7 mmol/24 h) was registered in 18 cases (14%; 12 of whom were in the D+ group; P = .047). Improvements in BMD were distributed evenly in this group. Compared to the main group with normal PtU-calcium at followup, there were no significant differences in Ca 2+ , PTH, 25-OH-D, bone markers, or eGFR at baseline or at follow-up (data not shown).
None of the patients with a history of nephrolithiasis reported any problems with nephrolithiasis during the study period. One male patient, not diagnosed earlier with nephrolithiasis and randomized to the DÀ group, developed kidney stones in the postoperative period and decided to end his participation several months after inclusion into the study; his preoperative PtUcalcium was 11.1 mmol/d. Twenty-six patients had increased levels of PTH at the 1-year follow-up, all of whom had a normalized total calcium. Two patients, one in each group, had increased PTH in combination with a high (normal) Ca 2+ (Ca 2+ 1.34 mmol/L; PTH 84 ng/L; DÀ and Ca 2+ 1.33 mmol/L; PTH 98 ng/ L; D+). Both patients had undergone a focused PTX with the removal of single adenomas (370 and 465 mg, both had normal PtU-calcium (2.3 and 5.2 mmol/d), and both improved in BMD (+4.8% lumbal, +1.9% hip and +1% hip and + 3.6% distal radius, respectively). Excluding these patients from the analyses did not change the results (data not shown).
In a multivariable model, adjusting for age, sex, smoking, diabetes, BMI, eGFR, baseline BMD, and vitamin D-group, baseline PtU-calcium in the highest quartile (>10 mmol/d) and baseline PTH concentration remained independently associated with increases in BMD in the hip and distal radius (Table IV) .
DISCUSSION
The main findings of this study are that baseline hypercalciuria was associated with bone recovery at all locations and that PtU-calcium > 10 mmol/ d was an independent predictor of bone 
23 (15) improvement in the distal hip and distal radius. Improvement in BMD in the distal radius was observed only in the D+ group, but improvements in BMD in the lumbar spine and hip were distributed evenly between groups, also among patients with persistent hypercalciuria at follow-up. The amount of calcium excreted in urine depends on several factors, such as sex, age, intestinal uptake, extent of bone resorption, and renal tubular function. The direct correlation between PtU-calcium and eGFR is consistent with earlier findings, and the association between PtU-calcium and bone markers strengthens the conclusion that hypercalciuria in pHPT is mainly a result of increased renal calcium load due to reversible bone resorption related to the hyperparathyroidism. 10 Also, the daily intake of Table II 
Fig 1.
A breakdown into baseline PtU-calcium quartiles shows that in both groups (DÀ and D+), the patients in the highest quartile (Q IV ; > 10 mmol/d) had the greatest improvements in BMD (Mann Whitney U test lumbar spine: P = .022; hip: P = .001; and distal radius: P = .004). Table III . Biochemistry at baseline (before operation) and change in bone mineral density postoperatively in groups of different 24-hour urinary calcium 1,000 mg calcium carbonate might have contributed both to an enhanced urinary calcium load and to bone recovery among our patients. It is possible that patients with persistent hypercalciuria at follow-up one year after PTX had less urinary calcium secretion in an earlier stage and had already sustained their bone gain. Similarly, patients with low urinary secretion at follow-up may have ongoing bone restitution. Perhaps a greater period of follow-up would be able to demonstrate improvement in bone density. The risk of kidney stones in pHPT is multifactorial and not explained solely by high PtU-calcium. 11 The complexity is well illustrated in patients with idiopathic hypercalciuria, the most common metabolic abnormality in patients with nephrolithiasis, also present in up to 20% of non-stone-forming, postmenopausal women with osteoporosis. 12 The prevalence of persistent hypercalciuria after successful PTX has been reported to be as great as 30%. 6, 13 Hypercalciuria in pHPT has been coupled to a renal tubular defect.
14 This defect in renal tubular function might be primary, as seen in patients with idiopathic renal hypercalciuria with decreased reabsorption of calcium and a longstanding stimulatory effect of the parathyroids or secondary to irreversible changes in renal hemodynamics causing hypercalcemic nephropathy.
Alternations in renal hemodynamics, with a greater renal vascular resistance compared to patients with primary hypercalciuria, has been reported.
14 Contrary to Palmieri et al, 6 persistent hypercalciuria after successful PTX was associated with an evenly distributed improvement in BMD. 6 This finding may be explained by differences in cohorts, especially the greater percentage of multiglandular disease in the Palmieri cohort. An increased risk of fractures in pHPT observed for up to 10 years before PTX has been reported. The risk returned to that of the general population within one year after PTX. 15 Bone enriched in cortical elements, such as the distal radius, has been shown to be affected earliest in pHPT. 5, 16, 17 The mechanism is not fully understood, but the remodeling process probably differs with the type of bone, cortical or cancellous, and between weight-bearing and non-weight-bearing bone. Effects of vitamin D may also differ between sites. 17 In this cohort, BMD increased similarly in the D+ and the DÀ group, except that the increase in distal radius was not seen in the DÀ group. A high baseline PtU-calcium was accompanied by a significant increase in BMD in all locations. The moderate effect of vitamin D substitution corresponds to results from other studies in which the expected effect of vitamin D on bone health did not materialize. 18 One of the main problems is that bone and kidney disease in pHPT may proceed silently and remain undiagnosed for an extended time. In affluent societies currently, the majority of pHPT patients do not present with overt symptoms. 19 In the present guidelines for patients with asymptomatic pHPT, PtU-calcium > 10 mmol/L is included among the indications for PTX when accompanied by an increase in the urinary biochemical stone risk. 19 Based on our findings of a strong association between hypercalciuria in the highest quartile and a BMD increase in all locations after PTX, we propose PtU-calcium above 10 mmol/L as an indication for PTX regardless of whether or not the pHPT patient is osteoporotic.
This study has some limitations. The presented results must be interpreted in light of the post hoc nature of the analyses. Based on our power calculations, the study cohort was well powered to demonstrate changes in BMD in the lumbar and hip areas but not in the radius where the effect size was much smaller. Furthermore, one must be aware of the fact that the results of this study may not be generalized to pHPT patients older than 80 years or patients with limited renal function. Other limitations are the study medication and the lack of a placebo group; however, post hoc analyses like this sometimes visualize significant factors that may remain undiscovered when only strict a priori analyses are considered. We suggest that the results of this study will be used as the base for more targeted studies. The strengths of the study are its prospective design and the close and standardized follow-up.
In conclusion, the study supports the notion that hypercalciuria in pHPT predicts reversible bone disease and strengthens the indication for PTX. ) and PTH remained independently associated with postoperatively increased BMD in the hip and distal radius; BMD in the hip was also dependent on age.
